FindMyKOL

Luxme Hariharan, MD

Enriched profile

Chief of Ophthalmology and Chief Population Health Officer, Dayton Children's Hospital (as of April 2024; current status unconfirmed) · Dayton Children's Hospital

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Dayton, OH · Midwest · United StatesSpecialtyPediatric Ophthalmology and Strabismus SpecialistFocusOphthalmology
Last active 2022FindMyKOL type: RegionalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2022NIH fundingNone on fileWhy? →

Luxme Hariharan is Chief of Ophthalmology and Chief Population Health Officer, Dayton Children's Hospital (as of April 2024; current status unconfirmed) at Dayton Children's Hospital.

Data verified 26 Oct 2026

Overview

Updated 31 Oct 2026

Luxme Hariharan, MD, is Chief of Ophthalmology and Chief Population Health Officer, Dayton Children's Hospital (as of April 2024. The public record shows 15 publications with 229 citations (h-index 7), centered on Ophthalmology. It also documents industry payments reported by 7 companies.

  • Top research focus: Ophthalmology
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 31 Oct 2026. Every fact links its source below.

Research focus

OpenAlex concept fingerprint
Ophthalmology

Drugs & molecules

across trials, industry payments and publications
CARBAGLUClinical trials—Industry payments1Publications—Cequageneric · CyclosporineClinical trials—Industry payments1Publications—CYSTADANEClinical trials—Industry payments1Publications—CYSTADROPSClinical trials—Industry payments1Publications—Eysuvisgeneric · Loteprednol etabonateClinical trials—Industry payments1Publications—Panhematingeneric · HeminClinical trials—Industry payments1Publications—Sylvantgeneric · SiltuximabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Topcon Medical Systems, Inc.Clinical trials—Industry payments2Apellis Pharmaceuticals, Inc.Clinical trials—Industry payments1CooperVision Inc.Clinical trials—Industry payments1EUSA Pharma (US) LLCClinical trials—Industry payments1Kala Pharmaceuticals, Inc.Clinical trials—Industry payments1Recordati_Rare_Diseases_Inc.Clinical trials—Industry payments1Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
0clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2022

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →

Clinical trials

We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →

Industry payments

Updated 31 Oct 2026

7 companies reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:

All 8 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 31 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.